Navigation Links
Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Date:11/3/2008

. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
6. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
7. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
9. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
10. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
11. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... ROSE SCIENCE SERIES Episode #9 - HEART DISEASE September 19, 2007, NEW ... The upcoming episode of the Charlie Rose Science Series will ... the leading cause of mortality ... biology and genetics of the disease, prevention and treatment, the ...
... ST. LOUIS, Sept. 14 Sigma-Aldrich Corporation,(Nasdaq: SIAL ... Life Sciences,Conference on Tuesday, September 25th at 1:00 PM ... via live audio broadcast over the,Internet available at ... this file. For the webcast on, http://ir.sigmaaldrich.com users ...
... and NORTH BRUNSWICK, New Jersey, September 14, Rosetta ... in,the development of microRNA-based diagnostics and therapeutics, announced,today ... at Maxim,Group,s Growth conference on Thursday, September 20, ... in New York. A live audio webcast ...
Cached Biology Technology:Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States 2Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference 2
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... state of the world,s oceans and fisheries led to inaccurate ... according to new analysis by an international team led by ... it,s like flipping a coin, half the time you get ... wrong answer," said Trevor Branch, a UW assistant professor of ...
... Coaching happens just about everywhere, and every day, with ... to smoothly functioning organizations, better productivity and potentially more ... Doctors or nurses can connect more with patients. So, ... goal, and it has been a major topic of ...
... Physicians caring for patients with sepsis may soon have ... Research led by Dr. Karel Tyml and his colleagues ... Institute have found that vitamin C can not only prevent ... Sepsis is caused by a bacterial infection that can begin ...
Cached Biology News:Scientists question indicator of fisheries health, evidence for 'fishing down food webs' 2Scientists question indicator of fisheries health, evidence for 'fishing down food webs' 3Coaching with compassion can 'light up' human thoughts 2Coaching with compassion can 'light up' human thoughts 3Coaching with compassion can 'light up' human thoughts 4Vitamin C: A potential life-saving treatment for sepsis 2
...
... High pH This pH 9.9 solution ... to immunohistochemical staining procedures. It is for ... on glass slides. For particular antigens, target ... effective. It should be noted that also ...
... A very potent Rnase ... effective over a broad range ... This protein does not inhibit ... polymerase, AMV and M-MLV reverse ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
Biology Products: